Biomarkers for Monitoring R-CHOP-associated Cardiotoxicity in Patients with Non-hodgkin Lymphoma.

INTRODUCTION

Antineoplastic therapy may exert toxic effects on multiple organ systems in patients with hematologic malignancies. This is particularly relevant for individuals with indolent non-Hodgkin lymphoma treated with anthracycline-containing regimens, which carry a well-documented risk of cardiotoxicity.

MATERIALS AND

METHODS

A case-control study was conducted at medical institutions in Samara, Russia, enrolling 72 patients diagnosed with grade 1-2 follicular B-cell non-Hodgkin lymphoma. All participants were administered six cycles of R-CHOP immunochemotherapy as clinically indicated. The primary objective was to identify early biomarkers of treatment-related cardiotoxicity.

RESULTS

The study identified three parameters as the most sensitive indicators of cardiovascular toxicity: prolongation of the corrected QT interval (QTc), reduction in left ventricular global longitudinal strain, and elevation of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) levels. Additionally, the authors propose prognostic models to predict the presence of cardiotoxicity at 3 and 6 months of treatment.

DISCUSSION: Comparison of the study's findings with previously published data revealed full consistency with the existing medical literature and further substantiates the authors' assertion regarding the prognostic utility of the identified laboratory and instrumental markers in the early detection of cardiotoxicity.

CONCLUSION

Incorporating these biomarkers into routine cardiovascular monitoring protocols facilitates early detection of cardiotoxicity in patients with hematologic malignancies, enabling timely therapeutic adjustments and optimizing clinical management.